在荷尔蒙疗法中加上硝拉巴里,减慢了前列腺前列腺癌的发病率,特别是在发生BRCA1/2突变的男子中,但副作用和与治疗有关的死亡有所增加。 Adding niraparib to hormone therapy slowed advanced prostate cancer, especially in men with BRCA1/2 mutations, but increased side effects and treatment-related deaths.

2025年10月7日《自然医学》发表的一项新研究发现,将PARP抑制剂硝酸盐添加到标准激素疗法中,大大减缓了前列腺癌的晚期发展,使患BRCA1/2突变的男子的肿瘤增长风险总体减少37%,48%。 A new study published in Nature Medicine on October 7, 2025, found that adding the PARP inhibitor niraparib to standard hormone therapy significantly slowed advanced prostate cancer progression, reducing tumor growth risk by 37% overall and 48% in men with BRCA1/2 mutations. 患者在症状恶化和改善生存趋势之前经历的时间较长,特别是在有DNA修复基因缺陷的患者当中。 Patients experienced longer time before symptom worsening and a trend toward improved survival, particularly among those with DNA repair gene defects. 然而,这种结合增加了副作用,包括贫血和高血压,提高了与治疗有关的死亡率,25%需要输血。 However, the combination increased side effects, including anemia and high blood pressure, and raised treatment-related death rates, with 25% needing transfusions. 研究人员敦促在诊断时进行基因检测,以确定符合资格的病人,并建议个人化的治疗决定。 Researchers urge genetic testing at diagnosis to identify eligible patients and recommend individualized treatment decisions.